Welcome to our dedicated page for Dianthus Therapeutics /DE/ SEC filings (Ticker: DNTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Dianthus Therapeutics /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Dianthus Therapeutics /DE/'s regulatory disclosures and financial reporting.
Dianthus Therapeutics, Inc. entered an underwriting agreement to conduct a public offering of its common stock and pre-funded warrants. The company is issuing 7,313,582 shares of common stock at $81.00 per share and pre-funded warrants for 402,468 shares at $80.999 per warrant.
The underwriters received a 30-day option to buy up to 1,157,407 additional shares at the public offering price, less discounts, and exercised this option in full on March 11, 2026. Including this option exercise, Dianthus expects net proceeds of approximately $673.5 million after underwriting discounts, commissions and estimated expenses.
The pre-funded warrants are exercisable at any time after issuance with a $0.001 per share exercise price, subject to beneficial ownership limits of 4.99%, 9.99% or 19.99%, adjustable up to 19.99% with at least 61 days’ prior notice.
Dianthus Therapeutics is offering 7,313,582 shares of common stock and pre-funded warrants to purchase 402,468 shares of common stock at a public offering price of $81.00 per share. The offering is subject to an underwriters’ option to purchase up to an additional 1,157,407 shares.
Delivery is expected on March 12, 2026. Net proceeds are estimated at approximately $585.4 million (or approximately $673.5 million if the underwriters’ option is exercised in full). Proceeds are intended to advance clinical and preclinical development, commercial readiness, working capital and general corporate purposes; management will have broad discretion over use.
Dianthus Therapeutics filed a preliminary prospectus supplement to offer $400,000,000 of common stock and, in lieu of shares for certain investors, pre-funded warrants to purchase common stock. The offering includes an underwriter option to purchase up to an additional $60,000,000.
The company’s common stock trades on Nasdaq under the symbol DNTH; the prospectus cites a reported sale price of $65.20 per share as of March 6, 2026. The prospectus states pro forma shares outstanding of 43,223,090 as of December 31, 2025. Net proceeds are intended to fund clinical and preclinical development, commercial readiness, working capital and general corporate purposes; management estimates cash will fund operations into late 2029.
Dianthus Therapeutics, Inc. files its annual report describing a clinical-stage pipeline focused on severe autoimmune diseases and complement biology. The company’s market value held by non-affiliates was $599.4 million based on its common stock closing price on June 30, 2025, with 44,471,094 shares outstanding as of March 4, 2026.
Dianthus’ lead antibody, claseprubart, targets active C1s in the classical complement pathway and is being tested in mid‑ to late‑stage trials in generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. A Phase 2 gMG study showed statistically significant and clinically meaningful improvements versus placebo on multiple endpoints with a safety profile comparable to placebo.
The company is advancing a planned global Phase 3 gMG trial, a pivotal Phase 3 CIDP trial that met an early responder target, and a Phase 2 MMN trial. Dianthus also licensed DNTH212, a bifunctional BDCA2 and BAFF/APRIL inhibitor, for development outside Greater China, with a Phase 1 study underway. The report outlines extensive IP protection, third‑party manufacturing arrangements, regional licensing with Tenacia and Leads, competitive dynamics in gMG, CIDP and MMN, and detailed U.S. and global regulatory frameworks for biologics.
Dianthus Therapeutics reported a larger 2025 net loss while advancing its autoimmune pipeline and securing an early positive signal in its key CIDP program.
For the year ended December 31, 2025, the company posted a net loss of $162.3 million, or $4.20 per share, driven mainly by higher research and development spending of $145.6 million and general and administrative expenses of $34.3 million. Cash, cash equivalents and investments totaled $514.4 million, which the company expects to fund operations into 2028.
Dianthus announced an early GO decision in its Phase 3 CAPTIVATE trial of claseprubart in CIDP after achieving 20 confirmed responders with fewer than 40 participants completing Part A, with no related serious infections or serious adverse events reported. The company plans to streamline Part B to 128 randomized patients and expects Part B top-line guidance by year-end 2026. It also plans a Phase 3 trial in generalized myasthenia gravis starting mid-2026, a Phase 2 readout in multifocal motor neuropathy in the second half of 2026, and Phase 1 healthy volunteer data for DNTH212 in the second half of 2026.
Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen report beneficial ownership of 2,981,674 shares of Dianthus Therapeutics common stock, representing 6.9% of the outstanding class as of the close of business on February 13, 2026.
The shares are held by Point72 Associates, LLC, an investment fund managed by Point72 Asset Management, with shared voting and dispositive power reported for each filing person. As of December 31, 2025, they had reported beneficial ownership of 1,166,088 shares, or 2.7% of the class. They certify the position is held on a passive basis and not for the purpose of changing or influencing control of Dianthus Therapeutics.
RA Capital Management and affiliates reported beneficial ownership of 2,611,733 shares of Dianthus Therapeutics, Inc. common stock, representing 6.0% of the class as of December 31, 2025. This includes 1,611,733 shares of common stock and pre-funded warrants exercisable for up to 1,000,000 additional shares.
The stake is held through RA Capital Healthcare Fund, L.P., for which RA Capital serves as investment adviser with delegated voting and dispositive power. The filers state the securities were not acquired to change or influence control of Dianthus and expressly disclaim status as a "group" and certain aspects of beneficial ownership beyond Section 13(d) reporting.
Dianthus Therapeutics reported a new equity award to its chief accounting officer, Edward Carr. On February 3, 2026, he received a stock option for 55,000 shares of common stock with an exercise price of $52.46 per share, expiring on February 3, 2036.
The option vests in equal monthly installments over four years after January 1, 2026, as long as he continues to serve the company on each vesting date. This filing reflects routine equity-based compensation rather than an open-market share purchase or sale.